Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala

Science

Volumn 308, Issue 5719, 2005, Pages 245-248

  Huber, Daniel ^a   Veinante, Pierre ^b   Stoop, Ron ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION ANALYSIS; AMINES; BIOCHEMISTRY; COMPLEXATION;

AMYGDALA; NEUROPEPTIDES; OXYTOCIN; VASOPRESSIN;

NEUROLOGY;

4 AMINOBUTYRIC ACID; IODINE 125; NEUROPEPTIDE; OXYTOCIN; OXYTOCIN ANTAGONIST; OXYTOCIN DERIVATIVE; OXYTOCIN RECEPTOR; OXYTOCIN[4 THREONINE 7 GLYCINE]; TETRODOTOXIN; UNCLASSIFIED DRUG; VASOPRESSIN; VASOPRESSIN DERIVATIVE; VASOPRESSIN RECEPTOR; VASOPRESSIN RECEPTOR ANTAGONIST; VASOTOCIN DERIVATIVE; DRUG DERIVATIVE; OXYTOCIN, TRI GLY; OXYTOCIN, TRI-GLY-;

BIOLOGY; NEUROLOGY;

AMYGDALOID NUCLEUS; ANIMAL TISSUE; ANXIETY; ARTICLE; AUTONOMIC NERVOUS SYSTEM; AUTORADIOGRAPHY; BRAIN CORTEX; CONTROLLED STUDY; FEAR; INHIBITORY POSTSYNAPTIC POTENTIAL; NERVE CELL NETWORK; NERVE POTENTIAL; NONHUMAN; PRIORITY JOURNAL; RAT; SYNAPTIC TRANSMISSION; VOLTAGE CLAMP; ANIMAL; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; IN VITRO STUDY; METABOLISM; NERVE CELL; PATCH CLAMP; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

AMYGDALA; ANIMALS; AUTORADIOGRAPHY; FEAR; GAMMA-AMINOBUTYRIC ACID; NEURONS; OXYTOCIN; PATCH-CLAMP TECHNIQUES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OXYTOCIN; RECEPTORS, VASOPRESSIN; TETRODOTOXIN; VASOPRESSINS;

EID: 16444367602     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1105636     Document Type: Article

References (29)

1. J. E. LeDoux, Annu. Rev. Neurosci. 23, 155 (2000).
2. P. Sah, E. S. Faber, M. Lopez De Armentia, J. Power, Physiol. Rev. 83, 803 (2003).
3. D. Pare, G. J. Quirk, J. E. Ledoux, J. Neurophysiol. 92, 1 (2004).
4. Z. Nie et al., Science 303, 1512 (2004).
5. M. H. Kang-Park, W. A. Wilson, S. D. Moore, Neuropharmacology 46, 1 (2004).
6. A. J. McDonald, S. J. Shammah-Lagnado, C. Shi, M. Davis, Ann. N.Y. Acad. Sci. 877, 309 (1999).
7. G. J. Quirk, E. Likhtik, J. G. Pelletier, D. Pare, J. Neurosci. 23, 8800 (2003).
8. M. D. Cassell, L. J. Freedman, C. Shi, Ann. N.Y. Acad. Sci. 877, 217 (1999).
9. P. Veinante, M. J. Freund-Mercier, J. Comp. Neurol. 383, 305 (1997).
10. G. Griebel et al., Proc. Natl. Acad. Sci. U.S.A. 99, 6370 (2002).
11. I. F. Bielsky, S. B. Hu, K. L. Szegda, H. Westphal, L. J. Young, Neuropsychopharmacology 29, 483 (2004).
12. R. Landgraf, I. D. Neumann, Front. Neuroendocrinol. 25, 150 (2004).
13. G. L. Kovacs, D. deWied, Pharmacol. Rev. 46, 269 (1994).
14. R. J. Windle, N. Shanks, S. L. Lightman, C. D. Ingram, Endocrinology 138, 2829 (1997).
15. J. N. Ferguson et al., Nature Genet. 25, 284 (2000).
16. F. Champagne, J. Diorio, S. Sharma, M. J. Meaney, Proc. Natl. Acad. Sci. U.S.A. 98, 12736 (2001).
17. T. L. Bale, A. M. Davis, A. P. Auger, D. M. Dorsa, M. M. McCarthy, J. Neurosci. 21, 2546 (2001).
18. M. Raggenbass, Prog. Neurobiol. 64, 307 (2001).
19. Y. F. Lu et al., Brain Res. 768, 266 (1997).
20. M. Condes-Lara, P. Veinante, M. Rabai, M. J. Freund-Mercier, Brain Res. 637, 277 (1994).
21. Materials and methods are available as supporting material on Science Online.
22. V. Savander, D. G. Go, J. E. Ledoux, A. Pitkanen, J. Comp. Neurol. 374, 291 (1996).
23. G. F. Koob, Eur. Neuropsychopharmacol. 13, 442 (2003).
24. K. Ebner, O. Bosch, S. A. Kromer, N. Singewald, I. D. Neumann, Neuropsychopharmacology 30, 223 (2005).
25. M. W. Sofroniew, Trends Neurosci. 6, 467 (1983).
26. C. J. de Vries, R. M. Buijs, Brain Res. 273, 307 (1983).
27. D. D. Francis, L. J. Young, M. J. Meaney, T. R. Insel, J. Neuroendocrinol. 14, 349 (2002).
28. D. A. Lubin, J. C. Elliott, M. C. Black, J. M. Johns, Behav. Neurosci. 117, 195 (2003).
29. We thank M. Raggenbass for introducing us to the exciting world of neuropeptides and F. Magara, E. Welker, M.-C. Broillet, and P. Magistretti for critical reading and comments to the manuscript. Supported by grants from the Swiss National Science Foundation, the Roche Research Foundation, and the Novartis and Théodore Ott Foundations.